SSA
MNPR icon

Schonfeld Strategic Advisors’s Monopar Therapeutics MNPR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Buy
+2,310
New +$143K ﹤0.01% 2165

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Schonfeld Strategic Advisors's MNPR Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Monopar Therapeutics (MNPR) in Q2 2026: 2,310 shares worth $214K. The stake represents ﹤0.01% of the portfolio and ranks #2165 among its holdings.

96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Schonfeld Strategic Advisors held 2,310 shares of Monopar Therapeutics worth $214K as of Q2 2026.
  • Monopar Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Monopar Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2165 holding.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.